|1.||Rothenberg, M L: 2 articles (03/2004 - 08/2001)|
|2.||Wilczynski, S: 2 articles (03/2004 - 08/2001)|
|3.||Alberts, D S: 2 articles (03/2004 - 08/2001)|
|4.||Liu, P Y: 2 articles (03/2004 - 08/2001)|
|5.||Livshits, M E: 2 articles (01/2000 - 01/2000)|
|6.||Gershanovich, M L: 2 articles (01/2000 - 01/2000)|
|7.||Sun, Jukui: 1 article (04/2010)|
|8.||Dong, Xiaodong: 1 article (04/2010)|
|9.||Gao, Xiaofei: 1 article (04/2010)|
|10.||Cao, Jinna: 1 article (04/2010)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
08/01/2001 - "The aim of this study was to evaluate the 2-year survival rate in a group of women in complete clinical remission (cCR) from Stage III ovarian cancer following front-line therapy who were then treated with a 6-month course of altretamine. "
03/01/2004 - "This report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy. "
03/01/1991 - "Hexamethylmelamine has been recognized as having useful single-agent activity for the treatment of ovarian cancer for the past 25 years, with some patients surviving disease-free for periods in excess of 12 years. "
11/01/1992 - "A Phase II trial of an intravenous preparation of Hexamethylmelamine was performed in ovarian cancer. "
11/01/1992 - "Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer."
01/01/1997 - "Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125."
01/01/1981 - "Phase II study of hexamethylmelamine for disseminated prostatic carcinoma."
12/01/1992 - "A total of 61 patients with recurrent or persistent clinically measurable platin-resistant epithelial ovarian carcinoma were treated with 260 mg/m2 oral hexamethylmelamine daily for 14 days, repeated at 4-week intervals. "
01/01/1983 - "Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma."
10/01/1981 - "The role of hexamethylmelamine in advanced ovarian carcinoma treatment."
12/01/1986 - "Hexamethylmelamine is an s-triazine that began clinical trials during the 1960s based on its level of antitumor activity in murine tumor models. "
04/01/1975 - "Both tumors undergo a significant and almost complete regression, even when well established, and hence may serve as model systems for the study of the mechanism of action of hexamethylmelamine."
01/01/1988 - "Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors."
08/01/1986 - "Hexamethylmelamine (HMM) was selected for development as an antineoplastic agent because it demonstrated activity in a variety of preclinical tumor models. "
01/01/1985 - "In vivo activity of hexamethylmelamine against some tumors may require metabolism by normal cells and subsequent transport of active species to the tumor site."
|4.||Breast Neoplasms (Breast Cancer)
06/01/1997 - "Hexamethylmelamine (HMM), a 1,3,5-triazine derivative has previously been recognized as an antitumor agent effective against lung, ovarian and breast cancer, but failed to show a significant cytotoxic activity in the present study. "
08/01/1979 - "Ninety-eight patients with metastatic breast cancer, heavily pretreated with other agents, were entered in a phase II trial of hexamethylmelamine (HEX). "
08/01/1979 - "Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study."
01/01/1978 - "Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy."
03/01/1991 - "Hexamethylmelamine use in the treatment of metastatic breast cancer."
02/15/1972 - "Hexamethylmelamine in inoperable bronchogenic carcinoma."
04/01/1975 - "Hexamethylmelamine is known to be effective in humans in the treatment of certain malignant tumors, especially bronchial carcinoma. "
07/01/1981 - "Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma."
12/01/1986 - "Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma."
12/01/1986 - "Mitomycin (10 mg/m2 iv on Day 1), vindesine (3 mg/m2 iv on Days 1 and 8), and hexamethylmelamine (100 mg/m2/day orally on Days 1-14) was administered to 32 patients with metastatic non-small cell bronchogenic carcinoma. "
|6.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)